 COPENHAGEN, Denmark, March 30, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS Nasdaq: EVAX, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it will present its full-year financial results for 2020 on April 6. 